KENUP-FOUNDATION
18.12.2020 15:00:16 CET | Business Wire | Press release
African reagent manufacturing for rapid testing kits and treatment for COVID-19 and other endemic diseases will be transformed by construction of a new Cape Biologix Technologies facility in Mauritius.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201218005388/en/
This will enable the company to scale up innovative plant-based manufacturing and to commercialise the successful development of plant based recombinant proteins and in particular, antibodies as a spin-off from the University of Cape Town. The manufacturing facility aims to ensure the supply of crucial reagents for the production of 100 million vaccines a month for distribution across Africa, the Caribbean and Pacific.
Initiated by kENUP Foundation, new financing from the European Investment Bank (EIB) and FIND (Foundation for Innovative New Diagnostics) for the EUR 47.5 million project was formally agreed earlier today. The EIB will provide EUR 33.3 million for the specialist manufacturing plant in Mauritius. This has been complemented by EUR 3.2 million provided by FIND that is being used to fund the rapid scale-up of the pilot phase production in Cape Town, South Africa.
“Scaling up medical innovation and specialist manufacturing is crucial to control COVID-19 and combat other diseases that can be treated, but where treatment remains a limited privilege. EIB is pleased to provide EUR 33.3 million to support Cape Biologix to expand pharmaceutical production, create jobs and increase access to affordable disease testing and treatment across Africa and around the world by increasing the affordability of key proteins. This new investment is bringing world class research from laboratories in Cape Town to improve the lives of millions of people. As part of Team Europe, the EIB is committed to working together with global partners to reduce the impact of the COVID-19 pandemic and improve public health in the years ahead.” said Ambroise Fayolle, EIB Vice President.
“Local innovation and manufacturing are critical to ensuring that quality tests can reach all who need them. We are very happy to build on our longstanding relationships in South Africa to work together on this transformative project with Cape Bio, in partnership with the EIB, translating exciting research into tangible products that will benefit everyone in the region. Building local capacity is not only needed today for COVID-19, but will also improve South Africa’s preparedness to respond to future threats.” said Dr Catharina Boehme, CEO of FIND.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005388/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom